Filing Details

Accession Number:
0001567619-19-009492
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-04-30 20:09:05
Reporting Period:
2019-04-26
Accepted Time:
2019-04-30 20:09:05
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1048477 Biomarin Pharmaceutical Inc BMRN Pharmaceutical Preparations (2834) 680397820
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1221590 Jacques Jean Bienaime C/O Biomarin Pharmaceutical Inc.
770 Lindaro St.
San Rafael CA 94901
Chief Executive Officer Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2019-04-26 3,000 $14.39 329,211 No 4 M Direct
Common Stock Disposition 2019-04-26 2,000 $82.44 327,211 No 4 S Direct
Common Stock Disposition 2019-04-26 800 $83.59 326,411 No 4 S Direct
Common Stock Disposition 2019-04-26 200 $84.41 326,211 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to buy Common Stock) Disposition 2019-04-26 3,000 $0.00 3,000 $14.39
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
18,000 2009-11-12 2019-05-11 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 181,341 Indirect Shares held by Jean-Jacques Bienaime Family Trust
Footnotes
  1. Trade made pursuant to a 10b5-1 plan executed on November 15, 2018.
  2. The price in column 4 is the weighted average price. The price actually received ranged from $82.085 to $83.03. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.
  3. The price in column 4 is the weighted average price. The price actually received ranged from $83.225 to $84.15. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.
  4. Reflects the number of options outstanding after the transactions from this specific stock option grant.